Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance.
- NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_assertion description "[To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, and in vivo pharmacodynamic effects of vorinostat in leukemia blasts.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance.
- NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_assertion evidence source_evidence_literature NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance.
- NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_assertion SIO_000772 23403629 NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance.
- NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_assertion wasDerivedFrom befree-20140225 NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance.
- NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_assertion wasGeneratedBy ECO_0000203 NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance.
- befree-20140225 importedOn "2014-02-25" NP433593.RATtILUS7H-5uSdQJ9Ab-9MB6Teg4XNt9e4QW4ilkXDxs130_provenance.